<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02277808</url>
  </required_header>
  <id_info>
    <org_study_id>Nebulizers for pentamidine</org_study_id>
    <nct_id>NCT02277808</nct_id>
  </id_info>
  <brief_title>Which Apparatus for Inhaled Pentamidine?</brief_title>
  <official_title>Which Apparatus for Inhaled Pentamidine? A Comparison of Drug Delivery to the Lung Between Two Nebulizers: The Respirgard II and the Isoneb.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The reference nebulizer used for pentamidine nebulization is currently the Respirgard II ®,
      disposable pneumatic nebulizer. Other nebulizers are on the market and appear to have
      comparable properties and better availability to the hospital. Several studies remark that
      all nebulizers with comparable properties could be used for the nebulization.The aim of our
      work will be to evaluate and compare the pulmonary deposition between the reference nebulizer
      Respirgard II ®, and one of these nebulizers available on the market, the Isoneb ®. We will
      measure and compare these data's for each of the nebulizers via nebulization Amikacine and
      urinary dosage.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amikacine urinary dosage</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Respirgard II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Determination of pulmonary deposition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isoneb</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Determination of pulmonary deposition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>500mg Amikacine (Amukin®) diluted in 4mL NaCl (0,9%)</intervention_name>
    <arm_group_label>Respirgard II</arm_group_label>
    <arm_group_label>Isoneb</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Respirgard II</intervention_name>
    <arm_group_label>Respirgard II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Isoneb®</intervention_name>
    <arm_group_label>Isoneb</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be in good health

        Exclusion Criteria:

          -  Known Tachycardia

          -  Renal Dysfunction

          -  Respiratory Diseases and history
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grégory Reychler, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques universitaires Saint-Luc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas Audag, PT</last_name>
    <email>nicolas.audag@uclouvain.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinique universitaire Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Reychler, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Gregory Reychler, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Oudyi M, Chaumuzeau JP, Diot P, Dubus JC; GAT (Groupe Aérosolthérapie de la SPLF). [Use of pentamidine nebulization in children]. Rev Mal Respir. 2012 May;29(5):656-63. doi: 10.1016/j.rmr.2012.02.003. Epub 2012 Mar 28. French.</citation>
    <PMID>22682591</PMID>
  </reference>
  <reference>
    <citation>McIvor RA, Berger P, Pack LL, Rachlis A, Chan CK. An effectiveness community-based clinical trial of Respirgard II and Fisoneb nebulizers for Pneumocystis carinii prophylaxis with aerosol pentamidine in HIV-infected individuals. Toronto Aerosol Pentamidine Study (TAPS) Group. Chest. 1996 Jul;110(1):141-6.</citation>
    <PMID>8681618</PMID>
  </reference>
  <reference>
    <citation>Kim CS, Garcia L, Wanner A. Actual pentamidine dose delivered by Respigard II nebulizer. Eur Respir J. 1995 Dec;8(12):2178-81.</citation>
    <PMID>8666114</PMID>
  </reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2014</study_first_submitted>
  <study_first_submitted_qc>October 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2014</study_first_posted>
  <last_update_submitted>October 28, 2014</last_update_submitted>
  <last_update_submitted_qc>October 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</investigator_affiliation>
    <investigator_full_name>G.Reychler</investigator_full_name>
    <investigator_title>Doctor in Physiotherapy</investigator_title>
  </responsible_party>
  <keyword>Pneumocystis</keyword>
  <keyword>Nebulizer</keyword>
  <keyword>Pentamidine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pentamidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

